Board of Directors

»»Board of Directors
Board of Directors 2017-07-07T16:03:11+00:00

Tom DietzThomas J. Dietz, PhD
Chairman of the Board
Chairman and CEO of Waypoint Holdings, LLC

Thomas Dietz is Chairman and CEO of Waypoint Holdings, LLC, a diversified financial holdings and services company. Dr. Dietz was co-CEO then CEO and a Director of Pacific Growth Equities, LLC, a San Francisco-based investment bank and institutional brokerage firm from 2004 to 2009, when the firm was acquired by Wedbush Securities. Dr. Dietz served as Head of the Investment Banking Division at Wedbush until November 2010. Prior to taking the CEO role at Pacific Growth, Dr. Dietz served as the Company’s Director of Equities Research and was an award-winning biotechnology and biopharmaceutical analyst. Dr. Dietz joined Pacific Growth in 1993. Previously, he was a member of the research faculty in the Department of Medicine, University of California, San Francisco and the VA Medical Center. Dr. Dietz also serves as the Chairman of AgBiome, LLC and Virobay, Inc, and is a board member of Paratek Pharmaceuticals (PRTK:Nasdaq) and Glialogix, Inc..

Thomas Dietz holds a Ph.D. in molecular biology and biochemistry from Washington University, St. Louis, and was a National Science Foundation Post-Doctoral Fellow.

Chuck BramlageChuck Bramlage, MBA
Director
CEO of Pearl Therapeutics

Chuck Bramlage has over 30 years of commercial, operational and transaction experience in the pharmaceutical industry across large, mid-size, and start-up companies. Mr Bramlage is currently the Chief Executive Officer of Pearl Therapeutics, Inc., a development stage start-up company focused on treatments for respiratory diseases that was acquired by AstraZeneca for up to $1.1 billion. He previously served as President of Pharmaceutical Products at Covidien and President of European Operations at Valeant Pharmaceuticals International. Earlier in his career, Mr. Bramlage held positions of increasing responsibility at GlaxoSmithKline including Vice-President of Respiratory Global Commercial Development and Vice-President of U.S. Respiratory and Cardiovascular Marketing, where he led teams responsible for the global launch of Seretide® / Advair® and the U.S. launch of Flovent® for Asthma and COPD. Mr. Bramlage began his pharma career at Merck where he held positions of increasing responsibility in sales, marketing, and management. In his career, Bramlage and his teams have launched over 40 prescription brands in 14 therapeutic areas. Mr. Bramlage received a B.S. in Marketing from The Ohio State University and an M.B.A. in Finance from the University of Dayton.

Ed EnglemanEdgar G. Engleman, MD
Director
Managing Partner, Vivo Capital

Edgar Engleman is a founding member of Vivo Capital, LLC (formerly Vivo Ventures), a healthcare/biotechnology investment firm with offices in Palo Alto, California as well as Shanghai, Beijing and Chengdu, China. Dr. Engleman is Professor of Medicine and Pathology at Stanford University School of Medicine, where he oversees the Stanford Blood Center and his own immunology research group. An editor of numerous scientific journals and the inventor of multiple patented technologies, he co-founded Cetus Immune (1981), Genelabs Technologies (1984), National Medical Audit (1985), Dendreon Corporation (1992), CellGate Technologies (1998) and SERC Therapeutics (2013).

Edgar Engleman currently serves on the boards of several private healthcare companies. He received his B.A. from Harvard University and his M.D. from Columbia University School of Medicine.

Jeffrey GlennJeffrey S. Glenn, MD, PhD
Director, Founder

Jeffrey Glenn is an Associate Professor of Medicine, Gastroenterology & Hepatology at Stanford University, and the Director of the Center for Hepatitis and Liver Tissue Engineering.

Dr. Glenn is an author on over 50 scientific articles and book chapters, is an inventor on over 30 issued and pending patent applications, and has been an active consultant for a variety of biotechnology and large pharmaceutical companies. His primary research interest is in molecular virology, with a strong emphasis on translating this knowledge into novel antiviral therapies. He is the principal investigator on multiple NIH grants, an elected member of the American Society for Clinical Investigation, and a member of the FDA Antiviral Drugs Advisory Committee.

Dr. Glenn’s work has focused on the function and cell biology of the hepatitis C virus (HCV) non-structural proteins, and has identified a collection of novel antiviral targets within HCV that can form the basis for new potential antiviral strategies. Dr. Glenn discovered the role of prenylation in the life cycles of hepatitis delta virus (HDV) and other viruses including as a trigger of virus assembly and a target for a promising antiviral treatment. Other interests include exploitation of hepatic stem cells, development of a small animal model for HCV, and engineered human liver tissues.

Jeffrey Glenn received his undergraduate degree from the University of California, Berkeley summa cum laude in Biochemistry and French Civilization, and both a Ph.D. in Biochemistry and Biophysics and M.D. from the University of California, San Francisco Medical Scientist Training Program. He completed an internship and residency in internal medicine, as well as a fellowship in gastroenterology, at Stanford University’s School of Medicine.

David ApelianDavid Apelian, MD, PhD
Director
Executive VP and Chief Medical Officer of Achillion Pharmaceuticals

Dr. Apelian’s clinical development and regulatory experience spans 17 years in all phases of development ranging from discovery to registration, across multiple therapeutic areas including GI, hepatology, immuno-oncology, infectious diseases, and rare diseases.  Dr. Apelian is currently Executive VP and Chief Medical Officer of Achillion Pharmaceuticals, Inc., a position he has held since 2013.  At Achillion, he was responsible for creating portfolio strategy and managing the company’s clinical development programs with a focus on hepatitis C.  He was instrumental in securing a partnership between Achillion and J&J, which resulted in a $225 million equity upfront payment and the potential for over $900 million in milestones.  Currently, he is leading the Achillion rare disease development program for novel small-molecule complement factor D inhibitors for alternative pathway-mediated diseases.  From 2005 to 2013 Dr. Apelian was Chief Medical Officer and subsequently head of all R&D and Regulatory Affairs for GlobeImmune, where he was a member of the management team that built the company to include multiple immuno-oncology and infectious disease programs, as well as helping to secure multiple corporate and government partnerships.  He was previously at Bristol-Myers Squibb where he served as Clinical Director in the Department of Clinical Design and Evaluation/Infectious Diseases Group and was Medical Leader for clinical development for Baraclude® (entecavir) for chronic HBV through NDA filing.  Baraclude is widely recognized as one of the most successful antiviral therapies, with revenues exceeding $1 billion per year.  Prior to that, Dr. Apelian was Clinical Director in the Department of Hepatology & Gastroenterology at Schering Plough, where he coordinated a supplemental NDA filing for interferon alpha-2b and ribavirin for the treatment of pediatric patients with chronic HCV.
Dr. Apelian completed his residency training in pediatrics at New York Hospital, Cornell Medical Center and is board certified in Pediatrics.  He received a PhD in Biochemistry from Rutgers University, an MD from the University of Medicine and Dentistry of New Jersey and an MBA from Quinnipiac University.  He earned a BA in Biochemistry from Rutgers University.

David CoryDavid A. Cory, RPh, MBA
President and Chief Executive Officer, Director, Business Founder

David Cory is an industry veteran with over 25-years of experience in large pharmaceuticals, emerging stage biotechnology, and specialty pharmaceutical organizations with an established track record of operational performance, including 5 successful Orphan Designation drug programs.

Cory is President and CEO, Director, and business founder of Eiger BioPharmaceuticals, leading the company since founding and responsible for negotiating the company’s multiple technology and product licenses from Stanford University, Merck, Nippon Kayaku, and Janssen. Previously, Cory was CEO of DiObex, a metabolic disease company. Cory was President and Chief Operating Officer of Prestwick Pharmaceuticals, an Orphan CNS specialty pharmaceutical company, which was acquired by Biovail for $160 million. Cory was Co-Founder and Acting Chief Commercial Officer at CoTherix, an Orphan Pulmonary Arterial Hypertension company, which was acquired by Actelion for $425 million. Cory began his start up career at InterMune, focused on developing Orphan products for Idiopathic Pulmonary Fibrosis, where he was a Senior Vice President, and a key executive in the company IPO, building and managing the company’s commercial organization, in-licensing 4 products and raising over $400 million in the capital markets. InterMune was acquired by Roche for $8 billion. Cory began his large pharma career in operating positions of increasing responsibility at The Upjohn Company, Glaxo, Glaxo Wellcome, and Glaxo Smith Kline where he led teams in CNS, Critical Care, Oncology, Infectious Disease, and Respiratory therapeutic areas, and directed 10 pharmaceutical product launches including Flolan (epoprostenol), the first Orphan Designation therapy approved for Pulmonary Arterial Hypertension.

David Cory earned a BS from the University of Cincinnati, College of Pharmacy and an MBA from the University of Maryland, University College.

About Eiger